S
Stephen Critchley
Researcher at Millennium Pharmaceuticals
Publications - 3
Citations - 1659
Stephen Critchley is an academic researcher from Millennium Pharmaceuticals. The author has contributed to research in topics: Ubiquitin & Proteasome. The author has an hindex of 3, co-authored 3 publications receiving 1439 citations.
Papers
More filters
Journal ArticleDOI
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Teresa A. Soucy,Peter G. Smith,Michael Milhollen,Allison Berger,James M. Gavin,Sharmila Adhikari,James E. Brownell,Kristin E. Burke,Cardin David P,Stephen Critchley,Courtney Cullis,Amanda Doucette,James J. Garnsey,Gaulin Jeffrey L,Rachel E. Gershman,Anna R. Lublinsky,Alice McDonald,Hirotake Mizutani,Usha Narayanan,Edward J. Olhava,Stephane Peluso,Mansoureh Rezaei,Michael D. Sintchak,Tina Talreja,Michael P. Thomas,Tary Traore,Stepan Vyskocil,Jie Yu,Julie Zhang,Lawrence R. Dick,Christopher F. Claiborne,Mark Rolfe,Joseph B. Bolen,Steven P. Langston +33 more
TL;DR: MLN4924 disrupts cullin-RING ligase-mediated protein turnover leading to apoptotic death in human tumour cells by a new mechanism of action, the deregulation of S-phase DNA synthesis, suggesting that NAE inhibitors may hold promise for the treatment of cancer.
Patent
Heteroaryl compounds useful as inhibitors of e1 activating enzymes
Christopher F. Claiborne,Stephen Critchley,Courtney Cullis,Steven P. Langston,Hirotake Mizutani,Edward J. Olhava,Stephane Peluso,Irache Visiers,Stepan Vyskocil +8 more
TL;DR: In this paper, the authors describe compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
Patent
Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes
TL;DR: The compounds of formula (I-A) as discussed by the authors inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.